Orien L Tulp^1-4*, Frantz Sainvil^1,2,5, Uzoamaka Nwokorie¹ and George P Einstein^1,2

¹University of Science Arts and Technology, Montserrat, Colleges of Medicine and Graduate Studies, Spain
²The Einstein Medical Institute, North Palm Beach, Florida, USA
³East West College of Natural Medicine, Sarasota, FL, USA
⁴Universidad de Sevilla, Seville, Spain
⁵Broward College, Davie, FL, USA

*Corresponding Author: Orien L Tulp, University of Science Arts and Technology, Montserrat, Colleges of Medicine and Graduate Studies, Spain.

Received: July 01, 2025; Published: July 14, 2025

Abstract

Resveratrol is a common phytochemical found in an abundance in nutritious and wholesome foods and thus has always likely been part of the human diet for many centuries. As such, resveratrol may contribute to the success of the French Paradox, where the inclusion of red wines is a familiar dietary addition and is associated with reduced incidence of cardiovascular disease. The primary metabolic action of resveratrol and related phenolic compounds likely rests in its potential antioxidant activity, being able to quench reactive free radicals (ROS) and other inflammatory activities in peripheral tissues. Wholesome foods are an established contributor to healthy benefits, sometimes attributed to the ratio of dietary fibers to macronutrient intake being consumed, with glycemic index also a significant factor. Resveratrol has been suggested as an adjunct in the clinical management of numerous metabolic disorders, including diabetes, obesity, hypertension, pre-eclampsia, and sickle cell disease among others associated with chronic inflammation. Thus, the purpose of this review is to examine the safety and efficacy of resveratrol in pregnancy. The results indicate that resveratrol is likely a safe and effective adjunct in treating the hypoxia and chronic inflammation of pregnancy, in addition to its applications in various hemoglobinopathies including sickle cell disease by inducing increased production of sickle-resistant fetal hemoglobin (HbF) in addition to reducing the magnitude of chronic inflammation, while enhancing oxygen delivery to peripheral tissues via actions of fetal hemoglobin. Thus, RSV may also be able to partially correct the effects linked to the globin chain imbalance in SCD patients, while at the same time facilitating oxygen transport to myoglobin in peripheral tissues due to a more favorable oxygen-delivering capacity than is observed in adult hemoglobin. The purpose of this paper is to review the biochemical, pharmacologic and potential toxicologic aspects of trans-resveratrol administration as an adjunct in the treatment of hemoglobinopathies including SCD during pregnancy.

Keywords: Resveratrol; Hydroxyurea; Sickle Cell Disease; Sickle Cell Anemia; Antioxidants; Sirtuins

References

1. Bille-Brahle NE., et al. “Red cell 2.3-diphosphoglycerate in pregnancy”. Acta Obstetricia et Gynecologica Scandinavica 1 (1979): 19-21.
2. Hu X-O and Zhang L. “Hypoxia and Mitochondrial Dysfunction in Pregnancy Complications)”. Antioxidants (Basel)3 (2021): 405.
3. , et al. “The Impact of Hypoxia in Early Pregnancy on Placental Cells”. International Journal of Molecular Sciences 22.18 (2021): 9675.
4. Ramli I., et al. “Effect of Resveratrol on Pregnancy, Prenatal Complications and Pregnancy-Associated Structure Alterations”. Antioxidants (Basel)2 (2023): 341.
5. Devlin TM. “Textbook of Biochemistry with clinical correlations”. 7^th Ed (2010).
6. Localzo, J and Harrison TR. “Harrison’s Principles of Internal Medicine”. 21^st (2022).
7. Goodman and Gillman. Pharmacological Basic of Therapeurics.
8. Kroner B., et al. “Sickle Cell Disease Implementation Consortium Pregnancy outcomes with hydroxyurea use in women with sickle cell disease”. American Journal of Hematology5 (2022): 603-612.
9. Agrawal RK., et al. “Hydroxyurea in Sickle Cell Disease: Drug Review”. Indian Journal of Hematology and Blood Transfusion 2 (2013): 91-96.
10. Rodrigue CM., et al. “Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation”. British Journal of Hematology2 (2001): 500-507.
11. Baur JA and Sinclair DA. “Therapeutic potential of resveratrol: The in vivo evidence”. Nature Reviews Drug Discovery 5 (2006): 493-506.
12. Leridon H and Slama R. “The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology”. Human Reproduction6 (2008): 1312-1319.
13. Pritisanac E., et al. “Fetal Hemoglobin and Tissue Oxygenation Measured With Near-Infrared Spectroscopy—A Systematic Qualitative Review”. Frontiers in Pediatrics (Neonatology) 9 (2021).
14. Tulp OL., et al. “EDITORIAL: Can trans-3'5'4-trihydroxystilbene (Resveratrol) become an effective adjunct in the treatment of Sickle Cell Disease?” (2025).
15. Bourassa DJ., et al. “Electron Scavenging not Free Radical Scavenging by Fullereen Materials Protects Against Mitochondrial Oxidative Stress in Complex Organisms”. EC Pharmacology and Toxicology6 (2020): 61-67.
16. Bell M. “A Historical Overview of Preeclampsia-Eclampsia”. Journal of Obstetric, Gynecologic, and Neonatal Nursing 5 (2010): 510-518.
17. Takaoka M and Takaoka M. “Resveratrol, a new phenolic compound, from Veratrum grandiflorum”. The Chemical Society of Japan 60 (1939): 1090-1100.
18. Renaud S., et al. “Wine, alcohol, platelets, and the French paradox for coronary heart disease”. Lancet 339 (1992): 1523-1526.
19. Mizuguchi Y., et al. “Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming”. Mitochondrion 34 (2017): 43-48.
20. Colica C., et al. “A Systematic Review on Natural Antioxidant Properties of Resveratrol”. Natural Product Communications 13(2018):1934578X1801300923.
21. Bo S., et al. “Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial”. Current Medicinal Chemistry 20 (2013): 1323-1331.
22. Nwokorie U., et al. “Use of trans-3'5'4-trihydroxystilbene (Resveratrol) as an adjunct in the treatment of Sickle Cell Disease”. Experimental Biology 35 (2021): S1.
23. Intagliata S., et al. “Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update”. Antioxidant (Basel) 8 (2019): 244.
24. Springer M and Moco S. “Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity”. Nutrients 1 (2019): 143.
25. Cote C D., et al. “Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network”. Nature Medicine 21 (2015): 498-505 (2015).
26. Longo VD., et al. “Sirtuins in aging and age-related disease”. Cell 126 (2001): 257-268.
27. Tulp OL. “Effect of aging and obesity on parameters of insulin, T4/T3 ratios, metabolic rates, sirtuins and longevity in congenic LA/Ntul//-cp rats”. Suntext Review of Medical and Clinical Research4 (2024): 1-9.
28. Wong RH., et al. “Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus”. Nutrition, Metabolism and Cardiovascular Diseases 26 (2016): 393-399.
29. Galiniak S., et al. “Health benefits of resveratrol administration”. Acta Biochimica Polonica 66 (2019): 13-21.
30. Berman AY., et al. “The therapeutic potential of resveratrol: a review of clinical trials”. Npj Precision Oncology 1 (2017): 35.
31. Cottart CH., et al. “Resveratrol bioavailability and toxicity in humans”. Molecular Nutrition and Food Research 54 (2010): 7-16.
32. Salehi B., et al. “Resveratrol: A Double-Edged Sword in Health Benefits”. Biomedicines 6 (2018): 91.
33. Shaito A., et al. “Potential Adverse Effects of Resveratrol: A Literature Review”. International Journal of Molecular Sciences 6 (2020): 2084.
34. Walle T., et al. “High Absorption But Very Low Bioavailability of Oral Resveratrol In Humans”. Drug Metabolism and Disposition 32 (2004): 1377-1382.
35. Kayle M., et al. “Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016-2020”. Morbidity and Mortality Weekly Report (MMWR)12 (2024): 248-254.
36. https://www.cdc.gov/mmwr/volumes/73/wr/mm7312a1.htm
37. FDA Newsroom. “FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease”. (2023).
38. Manai F and Amadio M. “Dimethyl Fumarate Triggers the Antioxidant Defense System in Human Retinal Endothelial Cells through Nrf2 Activation”. Antioxidants (Basel)10 (2022): 1924.
39. Rizvi SAA., et al. “Role of Traditional Medicine in Treatment and Prevention of Old and Emerging Diseases”. Biomolecules1442 (2022): 1-30.

Citation

Citation: Orien L Tulp., et al. “Trans-Resveratrol in Pregnancy, SCD and Woman’s Health". Acta Scientific Women's Health 7.8 (2025): 47-54.

Copyright

Copyright: © 2025 Orien L Tulp., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.